

Reflux Esophagitis - Pipeline Review, H2 2019

<https://marketpublishers.com/r/R7B30F39E205EN.html>

Date: September 2019

Pages: 98

Price: US\$ 2,000.00 (Single User License)

ID: R7B30F39E205EN

Abstracts

Reflux Esophagitis - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H2 2019, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the esophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules

developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 7, 7, 4, 1 and 1 respectively.

Reflux Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Reflux Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in
Therapeutics Development

Ahn-Gook Pharmaceutical Co Ltd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Daewoong Pharmaceutical Co Ltd

Eisai Co Ltd

Handa Pharmaceuticals LLC

Ilyang Pharmaceutical Co Ltd

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

RaQualia Pharma Inc

Sam-A Pharm Co Ltd

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

XuanZhu Pharma Co Ltd

Yooyoung Pharm Co Ltd

Yuyu Pharma Inc

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles

(esomeprazole + sodium bicarbonate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

azeloprazole sodium - Drug Profile

Product Description

Mechanism Of Action
R&D Progress
ceclazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-20043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-30065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
colesevelam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-14012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esomeprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-17DT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HND-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilaprazole DR - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
IYHCR-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-1366 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-3571 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

SA-15001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vonoprazan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XY-066 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YY-DXR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development
Milestones

Featured News & Press Releases

Aug 28, 2019: Sales of new gastric acid blocker K-Cab top 10 billion

May 09, 2019: Ironwood Pharmaceuticals to highlight IW-3718 data at Digestive
Disease Week 2019

Apr 25, 2019: Sihuan Pharm's innovative digestive system drug Anaprazole Sodium
achieved early completion of patient recruitment for phase II clinical trial in China

Mar 27, 2019: CJ Healthcare releases P3 trial results for gastroesophageal reflux
treatment

Oct 08, 2018: Ironwood Pharmaceuticals presents IW-3718 data at the American
College of Gastroenterology 2018 Annual Scientific Meeting

Jul 06, 2018: Ministry approves CJ Healthcares gastroesophageal reflux treatment

Jul 06, 2018: RaQualia Announces Receipt of Milestone Payment from CJ HealthCare

Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718

Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018

Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018

May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week 2018

Apr 16, 2018: First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD

Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease

Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017

Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by CJ HealthCare Corp, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co Ltd, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Handa Pharmaceuticals LLC, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals Inc, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Sam-A Pharm Co Ltd, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Takeda
Pharmaceutical Co Ltd, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by XuanZhu Pharma
Co Ltd, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yooyoung Pharm
Co Ltd, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuyu Pharma Inc,
H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2019
(Contd..1), H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2019
(Contd..2), H2 2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2
2019

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2
2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Ahn-Gook Pharmaceutical Co Ltd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Daewoong Pharmaceutical Co Ltd

Eisai Co Ltd

Handa Pharmaceuticals LLC

Ilyang Pharmaceutical Co Ltd

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

RaQualia Pharma Inc

Sam-A Pharm Co Ltd

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

XuanZhu Pharma Co Ltd

Yooyoung Pharm Co Ltd

Yuyu Pharma Inc

I would like to order

Product name: Reflux Esophagitis - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/R7B30F39E205EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R7B30F39E205EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970